https://www.selleckchem.com/pr....oducts/apoptozole.ht
The rate of the device-oriented endpoint was 22% in the BVS and 18% in the EES/BES group (p= 0.49). The patient-oriented composite endpoint occurred in 40% of BVS- and 43% of EES/BES-treated patients (p= 0.72) at 5 years. No acute coronary syndrome due to stent thrombosis was detected after 2 years. Complete BVS strut resorption was observed at 5 years in the OCT subgroup. Five-year clinical outcomes were similar between BVS and DES patients as well as angiographic outcomes in a selected subgroup. However, a definitive conclusion can
Curtir
Comentario
Compartilhar
